Frontal GABA in schizophrenia: A meta-analysis of 1H-MRS studies

World J Biol Psychiatry. 2021 Jan;22(1):1-13. doi: 10.1080/15622975.2020.1731925. Epub 2020 Mar 4.

Abstract

Objectives: The primary objective was to conduct a meta-analysis of studies comparing the GABA levels of schizophrenia patients (SZP) and healthy controls (HC) using proton magnetic resonance spectroscopy (1H-MRS) in the frontal cortex (FC) and its sub-regions.

Methods: We included studies published in English language that used 1H-MRS from MRI scanners having at-least 3 Tesla (3 T) magnetic field strength to measure GABA levels in SZP (n = 699) and HC (n = 718) in FC and its sub-regions. The outcome measures were the means and standard deviations of GABA levels and outcome measure was calculated using a random-effect model.

Results: In FC, medial prefrontal cortex (MPFC) and dorsolateral prefrontal cortex (DLPFC), there were no significant group differences. On excluding the outlier studies, the GABA levels were lower in patients with schizophrenia compared to healthy controls in FC (Hedges' g = -0.2; p = 0.02). In ACC, significant group difference was noted in GABA levels (Hedges' g = -0.25; p = 0.03) with patients values being lower that is more pronounced in the first episode schizophrenia patients (Hedges' g: -0.41; p = 0.003).

Conclusions: The available 1H-MRS studies suggest hypo-GABA ergia specifically in ACC and hint towards possible hypo GABA-ergic state in the FC. However, limitations of the analysis should be considered while interpreting the results.

Keywords: GABA; Gamma amino butyric acid; magnetic resonance spectroscopy; neuroimaging; schizophrenia.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Magnetic Resonance Imaging
  • Prefrontal Cortex / diagnostic imaging
  • Proton Magnetic Resonance Spectroscopy
  • Schizophrenia* / diagnostic imaging
  • gamma-Aminobutyric Acid

Substances

  • gamma-Aminobutyric Acid